Table 6 Selected ongoing trials of CAR-T cells therapy in AML.
From: T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Target | Phase | Study population | Intervention | Status | NCT.gov identifier |
|---|---|---|---|---|---|
CD33 | Phase I/II | Children and young adults with R/R AML | CD33 CAR-T cells | Recruiting | NCT03971799 |
CD33/CLL-1 | Phase I | R/R high-risk hematologic malignancies | CD33/CLL-1 cCAR T cells | Recruiting | NCT03795779 |
CD123/CLL-1 | Phase II/III | R/R AML | CD123/CLL-1 CAR-T cells | Recruiting | NCT03631576 |
CD123 | Phase I | R/R AML | allogeneic anti-CD123 CAR-T cells (UCART123) | Recruiting | NCT03190278 |
CD123 | Phase I | R/R AML after allo-HSCT | CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells | Recruiting | NCT03114670 |
CD123 | Phase I | CD123+ R/R AML and persistent/recurrent BPDCN | Autologous or allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T cells | Recruiting | NCT02159495 |
CD123 | Phase I/II | R/R AML | CD123 CAR-T cells | Recruiting | NCT04272125 |
Muc1/CLL-1/CD33/CD38/CD56/CD123 | Phase I/II | R/R AML | Muc1/CLL-1/CD33/CD38/CD56/CD123-specific gene-engineered T cells | Recruiting | NCT03222674 |
NKG2D | Phase I/II | Seven refractory cancers including AML | NKG2D CAR-T cells | Recruiting | NCT03018405 |
CD19 | Phase I/II | CD19+ R/R AML | CD19 CAR-T cells | Recruiting | NCT03896854 |
CLL-1, CD33 and/or CD123 | Phase I/II | R/R AML | CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells | Recruiting | NCT04010877 |
CD44v6 | Phase I/II | R/R AML or MM expressing CD44v6 | CD44v6 CAR-T cells | Recruiting | NCT04097301 |
